Strategic Partnerships Lexaria’s platform addresses oral delivery and CNS targeting, creating opportunities to partner with pharmaceutical companies seeking improved bioavailability and reduced side effects for weight management, diabetes, or neuroscience drugs.

BD Expansion Active participation in BIO and H.C. Wainwright conferences signals a focused business development push; leverage these events to identify licensees or co-development partners in mid to late-stage drug programs.

IP Stronghold A robust patent portfolio and ongoing filings around DehydraTECH can be positioned to prospective clients as a defensible differentiator for exclusive collaboration or licensing deals.

Portfolio Fit Recent focus on GLP-1 and next-gen weight loss therapies suggests licensing or collaboration opportunities with companies developing obesity, metabolic, and CNS-active drugs that could benefit from enhanced absorption and tolerability.

Early-Stage Readiness With a lean team and revenue under one million, there is an opportunity to package DehydraTECH as a co-development engagement or sponsored research program for pharma or biotech players seeking rapid tech validation.